Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Nintx Raises US$ 10 Million to Advance New Generation of Medicines Based on Brazilian Biodiversity
Dec 13, 2024
Contract Type
partnership
Sao PauloBiotechnologyHealth CarePharmaceutical
Description
Nintx, a biotech company, has raised an additional US$ 10 million to support their research and development plans for new drug programs, as well as to expand their laboratory and hire researchers. The investment aims to advance therapies to the end of preclinical studies, at which point it plans to license them to large pharmaceutical companies for clinical development and commercialization.
Company Information
Company
Nintx
Location
Sao Paulo, Sao Paulo, Brazil
About
Nintx develops a new generation of medicines leveraging biodiversity, primarily from Brazil. One of its key innovations is a broader approach to tackling multifactorial diseases, caused by genetic and environmental factors as well as their interactions via the human gut microbiome. Multifactorial diseases include metabolic, immunological, cancer, and brain disorders. Nintx develops therapies targeting biological pathways directly and indirectly through gut microbiome modulation—both closely linked to the onset or worsening of multifactorial diseases.